News & Articles
Arbovax Aims to Remove the Sting from Mosquito-Borne Diseases
You can't take the bite out of the mosquito, but a small Raleigh biotechnology company could become very big by taking the might out of that sometimes deadly bite. The company, Arbovax, was started by British-born entrepreneur Malcolm Thomas with a Business Development Loan for slightly more than $16,000 from the North Carolina
Biotechnology Center in 2006.

Arbovax, Inc. and Immunobiosciences, Inc announce a Collaborative Agreement on Dengue Vaccine Research
Arbovax, Inc (Arbovax) and Immunobiosciences, Inc (IBI) today
announced that they will initiate research collaboration on the development of safe and effective vaccines for dengue, a viral disease that is transmitted by mosquitoes. Arbovax will use their proprietary technology
to develop host range mutations of the dengue 2 virus and these mutants will then be formulated with antibody into immune complexes based on the IBI patented process. New inventions will be jointly held by both companies.

 
Welcome to Arbovax

ARBOVAX, Inc. has a unique technology that modifies arthropod-borne viruses (arboviruses) preventing them from replicating in mammalian cells. Arbovax will leverage this technology to facilitate development of a portfolio of improved vaccines against the worldwide threat of arthropod-borne diseases. read more

 
Spotlight on Dengue Fever

History of Dengue

Dengue Fever Perspectives
Occurance of Dengue Fevers

Arbovax.com © 2008. All rights reserved | Web Site developed by eCaribbean Ltd